Mario Campone
Institut de Cancérologie de l'Ouest(FR)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Cancer Genomics and Diagnostics
Most-Cited Works
- → Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer(2006)3,443 cited
- → Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer(2011)2,803 cited
- → Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer(2019)2,462 cited
- → Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer(2015)2,084 cited
- → Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer(2016)1,956 cited
- → MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer(2017)1,679 cited
- → Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial(2015)1,100 cited
- → Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study(2013)992 cited
- → Lomustine and Bevacizumab in Progressive Glioblastoma(2017)960 cited
- → Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study(2020)865 cited